QMed, Inc.
QMED
Other OTC0.00
USD
- -
- -
ISIN
US7479141092
Return %
Stock
S&P500
1Y
- -
26.84
3Y
-99.00
77.03
5Y
-99.00
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jane Ann Murray
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Eatontown United States of America
- IPO Date
- Jan 3, 2000
- Website
- qmedinc.com
- Similar Companies
- Business
- QMed, Inc. engages in developing, manufacturing, marketing, and selling medical devices and clinical information management systems, with a primary focus on products for coronary artery disease management. Its core offerings include the ohms/cad integrated coronary artery disease management system designed to assist health maintenance organizations in managing costs related to coronary artery disease. The company also produces and sells advanced medical systems that provide diagnostic interpretation for various disease states. Founded in 1983 and headquartered in Eatontown, New Jersey, QMed operates primarily within the healthcare sector, targeting health plans, federal government entities, and healthcare providers. In recent developments, QMed has expanded its portfolio and market reach through strategic partnerships, including a notable collaboration with Medical Tracking Solutions to integrate location and temperature data capabilities into its healthcare system platform via the iTraycer case and inventory management application. Additionally, QMed has embraced digital transformation by launching the Qmed+ platform, an online supplier directory that offers medtech manufacturers access to over 1,200 pre-qualified suppliers, featuring advanced search, communication, and proposal submission tools to streamline sourcing and accelerate medical device development. These initiatives represent a strategic shift towards strengthening its digital ecosystem and supplier network to better serve the medical device and diagnostics industry globally. QMed's evolution reflects a concerted push to enhance its clinical and operational solutions with technology-driven tools and increased market partnerships in the United States and internationally. The company maintains compliance with key industry certifications including ISO 9001 and ISO 13485 to meet quality and regulatory standards. This description covers QMed's main product lines, recent strategic partnerships, new digital platform launch, founding and headquarters, and its operational industry segments. It highlights QMed's developments through 2024-2025 to provide a comprehensive, up-to-date profile suitable for financial databases.